Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 6 of 6 entries
View as:
Phase: N/A
Priority: Normal
Start: 07/31/24
End: 07/31/34
Due: 07/31/35
Phase: N/A
Priority: Normal
Start: 07/31/25
End: 07/31/35
Due: 07/31/36
Phase: N/A
Priority: Normal
Start: 12/12/19
End: 05/31/24
Due: 05/31/25
Phase: N/A
Priority: Normal
Start: 06/23/25
End: 12/06/27
Due: 12/06/28
Phase: N/A
Priority: Normal
Start: 10/09/18
End: 12/31/23
Due: 12/31/24
Phase: N/A
Priority: Normal
Start: 10/25/17
End: 12/06/21
Due: 12/06/22
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Vitaccess Real MG Registry | NCT06064461 | Vitaccess Ltd | user2@example.com | None | 2024-07-31 | 2034-07-31 | 2035-07-31 | - | - | 2025-07-14 |
| Vitaccess Real CIDP Registry | NCT07006597 | Vitaccess Ltd | user2@example.com | None | 2025-07-31 | 2035-07-31 | 2036-07-31 | - | - | 2025-07-14 |
| The Impact of Myasthenia Gravis in the Real World | NCT04176211 | Vitaccess Ltd | user2@example.com | None | 2019-12-12 | 2024-05-31 | 2025-05-31 | - | - | 2025-07-14 |
| UK ENcorafenib and BInimetinib Real-world Study in Melanoma | NCT07022457 | Vitaccess Ltd | user2@example.com | None | 2025-06-23 | 2027-12-06 | 2028-12-06 | - | - | 2025-07-14 |
| The Impact of Charcot-Marie-Tooth Disease in the Real World | NCT03782883 | Vitaccess Ltd | user2@example.com | None | 2018-10-09 | 2023-12-31 | 2024-12-31 | - | - | 2025-07-14 |
| The Impact of Melanoma and Drug Treatment in the Real World | NCT03379454 | Vitaccess Ltd | user2@example.com | None | 2017-10-25 | 2021-12-06 | 2022-12-06 | - | - | 2025-07-14 |